Philips Archives - Page 18 of 19 - Medical Design Sourcing

Philips launches remote monitor and defibrillator for U.S. emergency responders

Royal Philips (NYSE:PHG) announced today that it launched its Tempus ALS remote monitoring and defibrillator system for pre-hospital settings.

Amsterdam-based Philips’ end-to-end system combining hardware and software to expand the pre-hospital scope for first responders received FDA 510(k) clearance and is now on the market in the U.S., the company said in a news release.

Tempus ALS includes a remote portable vital signs patient monitor (Tempus Pro) and a remote professional defibrilator (Tempus LS-Manual) that can be used separately, too. Additionally, the devices connect wirelessly to share data and transfer vitals, waveforms and images into Philips’ IntelliSpace Corsium software platform.

“In emergency situations, where seconds count, having access to advanced patient data collection and sharing and real-time secure data streaming, can help inform confident treatment and transport decisions outside the hospital,” Philips therapeutic care …

MedTech 100 roundup: Industry remains on the rise

The medtech industry continues to climb back up in the markets, following a landmark week with another move up toward its pre-COVID-19-pandemic highs.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — sat at 89.29 points at the end of last week (July 24). That total represents just a -3.3% dip from the Feb. 19 high point of 92.32, marking the smallest margin of decline over the past five months.

On July 22, the index reached 90.11 points, marking its highest point since that pre-pandemic high and the first and only time it has eclipsed 90 points since that day in February.

Medtech stocks saw a 0.44% increase from the 88.9-point total at the same time a week prior (July 17), highlighting a slight improvement after last week saw the industry inch back toward that pre-pandemic high.

Meanwhile, the S&P 500 Index saw a -0.3% decline from July 17 to July 24, and the Dow Jones Index fared slightl…

Paige pathology viewer lands FDA clearance

AI-aided pathology company Paige today announced it received FDA clearance for its FullFocus digital pathology image viewer for the purpose of primary diagnosis.

This clearance allows in vitro diagnostic (IVD) use of FullFocus with the FDA-authorized Philips Ultra Fast Scanner and paves the way for IVD use of FullFocus with additional IVD whole slide imaging (WSI) scanners, according to the New York-based company.

The foundation for the FullFocus viewer was created and validated at Memorial Sloan Kettering Cancer Center (MSK) to allow researchers and pathologists to view and navigate digital images of surgical pathology slides acquired on all major commercial brands of WSI scanners. After refinement based on 18 months of daily use for retrospective slide review by dozens of practicing pathologists at MSK, the viewer was further enhanced by Paige to meet the performance requirements for IVD use, with accurate color reproducibility, optimized viewing speeds and a…

Philips rises on Street-beating Q2 revenues

Royal Philips (NYSE:PHG) shares finished up today on second-quarter results that topped the consensus revenue forecast.

The Amsterdam-based company posted profits of $240.4 (€210 million), or 26¢ (€0.23) per share, on sales of $5 billion (€4.4 billion) for the three months ended June 30, 2020, for a -14.6% bottom-line slide on a sales decline of -5.9%.

Adjusted to exclude one-time items, earnings per share were 40¢ (€0.35), while the sales totals edged Wall Street projections, as analysts were looking for sales of $4.98 billion (€4.35 billion).

The impact of the COVID-19 pandemic included a decrease in consumer demand as hospital installations and elective procedures were postponed for long stretches throughout the last few months.

Additionally, Philips recorded a 19% comparable sales decrease for its personal health business and a 9% drop in diagnosis & treatment business. However, its connected care business saw 14% growth to help offset tho…

Philips launches new face scanning tech, partners with BioIntelliSense on telehealth

Royal Philips (NYSE:PHG) today announced two separate steps toward helping patients receive remote care as telehealth’s importance continues to grow.

Amsterdam-based Philips said today that it launched its Philips Respironics mask selector 3D facial scanning system for fitting masks and formed a strategic collaboration with BioIntelliSense to monitor at-risk patients from the hospital into the home.

The company touts its Respironics mask selector as the first and only clinically validated solution of its kind, as it helps providers fit nine of 10 patients with the right mask from the start, offering help in the shift toward digitized healthcare and reduced costs associated with fitting time and mask waste.

Using 3D camera technology, scans with the system capture 150 frames and 15 million points of facial geography data. Philips’ algorithm identifies the 46,200 data points most critical to providing an accurate and precise mask recommendation…

Magstim acquires high-density EEG tech from Philips

Neuroscience researchers worldwide use EGI’s Geodesic Sensor Net (GSN). [Image courtesy of Magstim]

Transcranial magnetic stimulation tech developer Magstim recently announced that it has purchased the product portfolio of Electrical Geodesics from Royal Philips (NYSE:PHG).

Financial terms of the deal were not disclosed.

Magstim will acquire EGI’s hardware, software and sensor nets assets and will immediately manage global sales, service and support, maintaining a presence in EGI’s Oregon office. The deal includes Philips supporting the transition through the end of 2020.

“This adds high-density EEG to our product portfolio supporting more than 1,200 research labs and clinics that focus on mental health, brain disorders and cognitive neuroscience,” said Lothar Krinke, CEO for Magstim, which is based in Whitland, U.K., and has U.S. head…

Philips wins FDA approval for new automated external defibrillators

This Philips image shows a HeartStart AED in action. [Image courtesy of Philips]

Royal Philips (NYSE:PHG) announced today that FDA has granted premarket approval for the company’s HeartStart FR3 and HeartStart FRx automated external defibrillators.

The HeartStart FR3 is a professional-grade AED. It includes advanced features for medical personnel and first-responders who need to treat a cardiac arrest.

The HeartStart FRx is a public-access AED. It features what Philips describes as intuitive, step-by-step voice instructions, including CPR guidance. The HeartStart FRx is intended for emergency use in workplaces, schools and other public spaces — as well as for medical professional use.

“We are pleased to receive premarket approval for our HeartStart FR3 and HeartStart FRx AEDs,” said Arman Voskerchyan, business leader of Therapeutic Care at Philips.

“Our industry-leading portfolio of AE…

Philips launches remote fetal monitor for high-risk pregnancies during COVID-19

Royal Philips (NYSE:PHG) announced today that it launched an addition to its remote patient monitoring platform for at-risk populations during the COVID-19 pandemic.

Amsterdam-based Philips added the Avalon CL fetal and maternal pod and patch for reducing unnecessary physical interactions between clinicians and patients to prevent transmission of the coronavirus. The patch makes up part of a high-risk pregnancy platform that includes Philips perinatal analytics and visualization, along with a portable, battery-operated fetal monitor.

The single-use, 48-hour disposable electrode patch placed on the mother’s abdomen allows for continuous, non-invasive monitoring for maternal heart rate, fetal heart rate and uterine activity. It only requires placement once, unlike traditional belts and sensors that require frequent repositioning, according to a news release.

Philips’ Avalon CL won CE Mark approval in 2019 and is commercially available in severa…

Philips launches Lumify tele-ultrasound system in Japan

Royal Philips (NYSE:PHG) announced today that its Lumify with Reacts handheld tele-ultrasound imaging system is commercially available in Japan.

Japan’s healthcare authority cleared Lumify for compatible handheld devices in its healthcare market to make high-quality, portable ultrasound available almost everywhere in the country, according to a news release.

Lumify is designed for use in places where quick and easy access to diagnostic ultrasound imaging is required and is suitable for point-of-care use in hospitals, ambulances, doctor’s offices and patients’ homes during GP visits as well. It allows clinicians to remotely collaborate by sharing ultrasound images in real-time.

Amsterdam-based Philips also noted the value of Lumify as telehealth’s importance continues to grow amid the COVID-19 pandemic. Meanwhile, specific to Japan, which Philips said has a declining birthrate and aging population, the need for medical diagnostic e…

Philips wins EUA for acute-care patient monitoring

Royal Philips (NYSE:PHG) announced today that it received FDA emergency use authorization (EUA) for its IntelliVue patient monitors and active displays.

The Amsterdam-based company’s IntelliVue monitors MX750/MX850 and active displays AD75/D85 received authorization to support infection-control protocols and provide caregivers information remotely during the ongoing COVID-19 pandemic.

Both sets of IntelliVue products received CE Mark approval last year and the MX750 patient monitor already received EUA in April. The latest EUA allows Philips to begin delivering the remote monitoring products to hospitals in the U.S., while it is preparing to submit to the FDA for 510(k) clearance this year.

The monitors and active displays include Philips’ IntelliVue Horizon Trends information view that shows deviations in vital signs. It also features an alarm advisor and alarm reporting to reduce caregivers’ alarm fatigue. Philips noted in a news rele…

Philips launches clinical trial accelerator

Royal Philips (NYSE:PHG) announced that it launched the clinical trial accelerator on its Philips HealthSuite to improve trial efficiency.

The Amsterdam-based company’s accelerator includes a new, tailored set of capabilities to enable life science organizations to integrate, analyze and store clinical and patient-reported data from multiple sources in an effort to provide actionable insights for better, faster decision-making, according to a news release.

Philips HealthSuite uses HIPAA-compliant, secure cloud capabilities to allow for patient-centric trials to take place at home and manage the collection of data while offering security and compliance as it sets out to increase efficiency in trial design.

“Philips HealthSuite already provides cloud-based services and tools to a wide array of healthcare organizations, and with clinical trial accelerator we have created a tailored set of capabilities to support life science organizations,” Philips H…

Philips patient monitors to add more Masimo technology

Masimo (NSDQ:MASI) and Royal Philips (NYSE:PHG) announced today that Philips will integrate additional Masimo measurement technologies into certain IntelliVue MX-series monitors to help clinicians assess cerebral oximetry and ventilation status.

Masimo noninvasive measurements, such as SET measure-through motion and Low Perfusion pulse oximetry and advanced rainbow SET Pulse CO-Oximetry parameters like noninvasive hemoglobin (SpHb), have long been available on a wide range of Philips multi-parameter monitors.

In 2016, Masimo and Philips entered into a multi-year business partnership with Philips agreeing to integrate Masimo’s SedLine brain function monitoring, O3 regional oximetry and Nomoline capnography tech into certain Philips IntelliVue monitors.

The latest agreement will add Masimo’s NomoLine and O3 measurements to Philips patient monitors to provide capnography and regional cerebral oximetry.

NomoLine capnography and O3 regional oxi…